An X-ray of the human shoulderPhotodisc / Getty
From Time Magazine:
An experimental drug has successfully reduced hip and spine fractures in the two largest patient populations at risk for osteoporosis — postmenopausal women and men being treated for prostate cancer — according to two major studies published online on Aug. 11 by the New England Journal of Medicine. The new compound, denosumab, is being reviewed by the Food and Drug Administration. If approved, it has the potential to become a standard treatment for certain patients.
Read more ....
